Hsp90/Cdc37 Chaperone/co-chaperone complex, a novel junction anticancer target elucidated by the mode of action of herbal drug Withaferin A
2011

Withaferin A as a Potential Anticancer Agent Targeting Hsp90/Cdc37 Complex

publication Evidence: moderate

Author Information

Author(s): Grover Abhinav, Shandilya Ashutosh, Agrawal Vibhuti, Pratik Piyush, Bhasme Divya, Bisaria Virendra S, Sundar Durai

Primary Institution: Indian Institute of Technology (IIT) Delhi

Hypothesis

Can Withaferin A disrupt the Hsp90/Cdc37 chaperone/co-chaperone interactions to enhance tumor arresting activity?

Conclusion

Withaferin A is a potent anticancer agent that disrupts the stability of the Hsp90/Cdc37 complex, leading to enhanced tumor cell apoptosis.

Supporting Evidence

  • The study demonstrated that Withaferin A can disrupt the Hsp90/Cdc37 complex, which is crucial for cancer cell survival.
  • Molecular dynamics simulations showed that the binding of Withaferin A to the complex is thermodynamically stable.
  • Withaferin A's ability to inhibit the association of Hsp90 with its co-chaperone Cdc37 was supported by significant binding energy values.

Takeaway

This study shows that a natural compound called Withaferin A can help fight cancer by stopping a protein complex that cancer cells need to grow.

Methodology

The study used molecular docking and molecular dynamics simulations to analyze the interaction between Withaferin A and the Hsp90/Cdc37 complex.

Digital Object Identifier (DOI)

10.1186/1471-2105-12-S1-S30

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication